Arbutus Biopharma Corp Revenue per Employee (ABUS), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Arbutus Biopharma Corp  (NASDAQ: ABUS)
 

Arbutus Biopharma's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Arbutus Biopharma's Revenue per employee grew on a trailing twelve month basis to $ 9,564,211, above the company average.
Within the Healthcare sector Employees of 3 other companies have achieved higher revenue per employee. While Arbutus Biopharma's total ranking has deteriorated compared to the previous quarter from 80 to 92. Arbutus Biopharma has 19 employees.


What is Sales per Employee Ratio?






Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ABUS Revenue per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Revenue Change -90.56 % 10054.54 % -33.23 % -60.49 % 522.19 %
Sales per Employee (TTM) $ 9,564,211 10,076,053 741,211 768,737 811,368
ABUS's Total Ranking # 92 # 80 # 2368 # 2191 #
Seq. Revenue Change -99.43 % 16943.39 % 98.68 % -95.07 % 508.79 %

ABUS Company Profile >> Back to ABUS Efficiency Comparisons >> Compare ABUS Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 4
Healthcare Sector # 4
Overall Market # 92

Revenue per Employee Statistics
High Average Low
$ 10,076,053 $ 1,082,964 $ 59,105
(Mar 31 2026)   (Mar 31 2017)



Financial Statements
Arbutus Biopharma's Revenue MRQ $ 1 Millions Visit ABUS's Income Statement
Arbutus Biopharma's Revenues TTM $ 182 Millions Visit ABUS's aggregate revenue growth
What are ABUS's Sales? Visit ABUS's Sales by Segment




Other Ratios
Arbutus Biopharma's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
ABUS's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for ABUS's Competitors
Revenue per Employee for ABUS's Suppliers
Revenue per Employee for ABUS's Customers

You may also want to know
ABUS's Sales Growth Rates ABUS's Pe Price to earnings ratio ABUS's Receivables Turnover Ratio ABUS's Stock Quote
ABUS's Net Income Growth Rates ABUS's Ps Price to Sales ratio ABUS's Sales per Employee ABUS's Asset Turnover Ratio
ABUS's Net Margin ABUS's Pb Price to Book ratio ABUS's Financial Strength Ratios ABUS's Dividend Payout Ratio
Date modified: 2026-09-03T23:29:01+00:00




Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Jun 30 2026Number of Employees Jun 30 2026
Arbutus Biopharma Corp  9,564,210.53 $ 181.720  Million 19 
Ligand Pharmaceuticals Incorporated  6,181,744.68 $ 290.542  Million 47 
Anika Therapeutics Inc   5,779,523.81 $ 121.370  Million 21 
Xeris Biopharma Holdings Inc   5,160,215.38 $ 335.414  Million 65 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.